Comparison of Paravertebral Versus Epidural Block for Post-thoracotomy Pain Control

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHospital de Clinicas de Porto Alegre

About this trial

This is a randomized, assessor-blinded, non-inferiority clinical trial comparing continuous thoracic paravertebral block (BPV) versus continuous thoracic epidural block (BPD) for postoperative pain control in adult patients undergoing elective open thoracotomy with one-lung ventilation. The primary outcome is the mean pain intensity at rest assessed by the Numeric Verbal Scale (NVS 0-10) during the first 48 hours after surgery. A total of 80 participants will be randomized 1:1 at Hospital de Clínicas de Porto Alegre, Brazil. The study aims to determine whether BPV provides non-inferior analgesia compared to BPD, with a potential advantage of less hemodynamic interference and better postoperative mobilization.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 years or older;

Elective thoracic surgeries requiring open thoracotomy;

American Society of Anesthesiologists (ASA) physical status I to III.

Disqualifiers

Pregnancy or lactation;

Urgent or emergency surgeries;

Contraindications to epidural catheter insertion or neuraxial anesthesia;

Infection at the proposed block site;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Continuous Thoracic Paravertebral Block

    Procedure/Surgery

    Participants randomized to the continuous thoracic paravertebral block (BPV) group. At the end of surgery and before chest tube placement, a paravertebral catheter is inserted under direct thoracoscopic vision (without ultrasound) using a Tuohy needle. A bolus of ropivacaine 0.375% (15 mL, fractionated) is administered, followed by continuous infusion of bupivacaine 0.125% at 0.10 mL/kg/h. The target level is T5-T7 (or T5-T9). The catheter remains in place for at least 48 hours postoperatively.

  • Continuous Thoracic Epidural Block

    Procedure/Surgery

    Participants randomized to the continuous thoracic epidural block (BPD) group. At the beginning of surgery, an epidural catheter is inserted at the thoracic level using the loss-of-resistance technique. A bolus of ropivacaine 0.375% (15 mL, fractionated) is administered, followed by continuous infusion of bupivacaine 0.125% at 0.10 mL/kg/h. The target level is T5-T7 (or T5-T9). The catheter remains in place for at least 48 hours postoperatively.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Paravertebral Block GroupExperimental treatment 1 intervention
Group B: Epidural Block GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Mean pain intensity at rest during the first 48 hours after surgery

Mean of the pain scores at rest measured by the Numeric Verbal Scale (NVS 0-10) at 6, 12, 24, and 48 hours postoperatively. This composite measure is the primary endpoint for the non-inferiority comparison between continuous thoracic paravertebral block and continuous thoracic epidural block.

Time frame
6, 12, 24, and 48 hours after surgery

Secondary outcomes

1

Pain on movement

Pain intensity during movement (e.g., coughing, sitting, or walking) assessed by Numeric Verbal Scale (0-10) at 6, 12, 24, and 48 hours postoperatively.

Time frame
6, 12, 24, and 48 hours after surgery
2

Total opioid consumption in the first 48 hours

Total opioid consumption (converted to intravenous morphine equivalents in mg) from the end of surgery until 48 hours postoperatively.

Time frame
0 to 48 hours after surgery
3

Block-related complications

Incidence of complications related to the regional blocks, including hypotension (systolic BP \< 100 mmHg or \>20% drop from baseline), urinary retention requiring catheterization, motor block (modified Bromage scale), and technical failure of the block.

Time frame
During the first 48 hours after surgery
4

Clinically significant pulmonary and cardiovascular complications

Incidence of clinically significant pulmonary complications (e.g., atelectasis requiring intervention, pneumonia) and cardiovascular complications (e.g., arrhythmias requiring treatment, ischemic events) in the first 72 hours after surgery.

Time frame
Up to 72 hours after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: